R Morant
Nierenzellkarzinom. Fortschritte in der Systembehandlung
Gramann T, Schmid H, Morant R. Nierenzellkarzinom. Fortschritte in der Systembehandlung. InFo Onkol Hämatol 2017; 5
01.01.2017Nierenzellkarzinom. Fortschritte in der Systembehandlung
01.01.2017InFo Onkol Hämatol 2017; 5
Gramann Tobias, Schmid Hans-Peter, Morant R
Multidisciplinary care in patients with prostate cancer: room for improvement
Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.
01.01.2013Multidisciplinary care in patients with prostate cancer: room for improvement
01.01.2013Support Care Cancer 2013; 21:2327-33
Strebel RT, Winterhalder R, Morant R, Pless M, U Huber, Fehr Martin, Gillessen S, Schmid Hans-Peter, Sulser T, Cathomas R
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR
Morant R, Vuaroqueaux V, Diener P, Fürstenberger G, Horica C, Németh T, Sulmoni M, Eppenberger U, Eppenberger-Castori S. Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR. Int J Clin Pharmacol Ther 2011; 49:86-7.
01.01.2011Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR
01.01.2011Int J Clin Pharmacol Ther 2011; 49:86-7
Morant R, Vuaroqueaux V, Diener Pierre-André, Fürstenberger G, Horica C, Németh T, Sulmoni M, Eppenberger U, Eppenberger-Castori S
Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience
Münger-Beyeler C, Bernhard J, Rufibach K, Morant R, Schmid H. Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008; 16:461-7.
01.05.2008Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience
01.05.2008Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008; 16:461-7
Münger-Beyeler C, Bernhard J, Rufibach K, Morant R, Schmid Hans-Peter
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
Steinbild S, Burkholder I, Edler L, Hanauske A, Hochhaus A, Strumberg D, Dittrich C, Gillessen Sommer S, Morant R, Frost A, Mross K, Scheulen M. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British journal of cancer 2007; 97:1480-5.
03.12.2007A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
03.12.2007British journal of cancer 2007; 97:1480-5
Steinbild S, Burkholder I, Edler L, Hanauske A-R, Hochhaus A, Strumberg D, Dittrich C, Gillessen Sommer Silke, Morant R, Frost A, Mross K, Scheulen M
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
Glaus A, Böhme C, Thürlimann B, Ruhstaller T, Hsu Schmitz S, Morant R, Senn H, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6.
01.05.2006Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
01.05.2006Ann Oncol 2006; 17:801-6
Glaus A, Böhme Christel, Thürlimann Beat, Ruhstaller Thomas, Hsu Schmitz S F, Morant R, Senn H J, von Moos R
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Seium Y, Morant R, Bauer J, Trembleau C, Allal A, Philippe M, Mentha G, Gervaz P, Ruhstaller T, Stupp R, Roth A. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:762-6.
01.05.2005Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
01.05.2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:762-6
Seium Y, Morant R, Bauer J, Trembleau C, Allal A, Philippe M, Mentha G, Gervaz P, Ruhstaller Thomas, Stupp R, Roth A D
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny T, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer S, Dietrich D, Bernhard J, Schmid H. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. British journal of cancer 2004; 90:1312-7.
05.04.2004Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
05.04.2004British journal of cancer 2004; 90:1312-7
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny Thomas, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer Silke, Dietrich D, Bernhard J, Schmid H-P
Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.
01.08.2002Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
01.08.2002European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann Beat, Bernhard J, Hsu Schmitz S-F, Schmid H-P
Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
D'Addario G, Morant R, Boehme C, Cerny T. Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Onkologie 2002; 25:152-7.
01.04.2002Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
01.04.2002Onkologie 2002; 25:152-7
D'Addario G, Morant R, Boehme C, Cerny Thomas
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann B, Fey M, Borner M, Maibach R, Bernhard J, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8.
01.02.2000Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
01.02.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann Beat, Fey M F, Borner M, Maibach R, Bernhard J, Hering F
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.
01.06.1999Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
01.06.1999Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S F, Thürlimann Beat, Hürny C
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.
01.06.1999Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
01.06.1999European journal of cancer (Oxford, England : 1990) 1999; 35:913-20
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Thürlimann Beat, Schmitz S F, Castiglione-Gertsch M, Hürny C
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Thürlimann B, Castiglione M, Hsu-Schmitz S, Cavalli F, Bonnefoi H, Fey M, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24.
01.06.1997Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
01.06.1997European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24
Thürlimann Beat, Castiglione M, Hsu-Schmitz S F, Cavalli F, Bonnefoi H, Fey M F, Morant R, Löhnert T, Goldhirsch A
[Osteopenia in beta-thalassemia major]
Brändle M, Galeazzi R, Morant R, Oesterle M. [Osteopenia in beta-thalassemia major]. Schweizerische medizinische Wochenschrift 1996; 126:1867-74.
02.11.1996[Osteopenia in beta-thalassemia major]
02.11.1996Schweizerische medizinische Wochenschrift 1996; 126:1867-74
Brändle Michael, Galeazzi R L, Morant R, Oesterle M
[MALT-type low-grade B-cell lymphomas of the stomach and Helicobacter pylori]
Binek J, Morant R, Weber A, Schmid U, Hammer B. [MALT-type low-grade B-cell lymphomas of the stomach and Helicobacter pylori]. Schweizerische medizinische Wochenschrift 1996; 126:841-4.
11.05.1996[MALT-type low-grade B-cell lymphomas of the stomach and Helicobacter pylori]
11.05.1996Schweizerische medizinische Wochenschrift 1996; 126:841-4
Binek Janek, Morant R, Weber A, Schmid U, Hammer B
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Thürlimann B, Morant R, Jungi W, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2:61-5.
01.01.1994Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
01.01.1994Support Care Cancer 1994; 2:61-5
Thürlimann Beat, Morant R, Jungi W F, Radziwill A
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
Morant R, Thürlimann B, Jungi W, Schmid L, Holdener E, Schmid U, Senn H. [Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]. Schweiz Med Wochenschr 1991; 121:344-6.
09.03.1991[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
09.03.1991Schweiz Med Wochenschr 1991; 121:344-6
Morant R, Thürlimann Beat, Jungi W F, Schmid L, Holdener E, Schmid U, Senn H J